In neuroblastoma models, anti-GD2 WT IL-2 immunocytokines enhanced antitumor efficacy and immune cell infiltration when delivered intratumorally, compared with intravenous injection or unconjugated IL-2 treatment (39). This evidence concerns the gene IL2 and neuroblastoma.